Your browser doesn't support javascript.
loading
Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
Song, Lianxi; Xu, Qinqin; Lizaso, Analyn; Zhang, Yongchang.
Afiliação
  • Song L; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
  • Xu Q; Qinghai Provincial People's Hospital, Xining, People's Republic of China.
  • Lizaso A; Burning Rock Biotech, Guangzhou, People's Republic of China.
  • Zhang Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China. Electronic address: zhangyongchang@csu.edu.cn.
J Thorac Oncol ; 16(3): 349-351, 2021 03.
Article em En | MEDLINE | ID: mdl-33641716
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Idioma: En Ano de publicação: 2021 Tipo de documento: Article